nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLCO1B1—Methotrexate—muscle cancer	0.0671	0.137	CbGbCtD
Sirolimus—CYP3A7—Vincristine—muscle cancer	0.065	0.133	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.065	0.133	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—muscle cancer	0.0515	0.105	CbGbCtD
Sirolimus—CYP3A5—Vincristine—muscle cancer	0.0488	0.0995	CbGbCtD
Sirolimus—CYP3A5—Etoposide—muscle cancer	0.0447	0.0912	CbGbCtD
Sirolimus—ABCB1—Vincristine—muscle cancer	0.0317	0.0647	CbGbCtD
Sirolimus—ABCB1—Etoposide—muscle cancer	0.0291	0.0593	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—muscle cancer	0.0198	0.0405	CbGbCtD
Sirolimus—ABCB1—Methotrexate—muscle cancer	0.0192	0.0392	CbGbCtD
Sirolimus—CYP3A4—Vincristine—muscle cancer	0.019	0.0388	CbGbCtD
Sirolimus—CYP3A4—Etoposide—muscle cancer	0.0174	0.0355	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—muscle cancer	0.0119	0.0242	CbGbCtD
Sirolimus—MTOR—hindlimb—muscle cancer	0.0111	0.112	CbGeAlD
Sirolimus—MTOR—appendage—muscle cancer	0.00954	0.0957	CbGeAlD
Sirolimus—EIF4E—embryo—muscle cancer	0.00819	0.0821	CbGeAlD
Sirolimus—EIF4E—renal system—muscle cancer	0.0062	0.0622	CbGeAlD
Sirolimus—EIF4E—head—muscle cancer	0.00415	0.0416	CbGeAlD
Sirolimus—EIF4E—testis—muscle cancer	0.00401	0.0402	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—muscle cancer	0.00393	0.0394	CbGeAlD
Sirolimus—MTOR—embryo—muscle cancer	0.00317	0.0318	CbGeAlD
Sirolimus—FGF2—tendon—muscle cancer	0.00295	0.0296	CbGeAlD
Sirolimus—FGF2—vagina—muscle cancer	0.00274	0.0275	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—muscle cancer	0.00249	0.025	CbGeAlD
Sirolimus—FGF2—testis—muscle cancer	0.00244	0.0245	CbGeAlD
Sirolimus—MTOR—renal system—muscle cancer	0.0024	0.024	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—muscle cancer	0.00224	0.0225	CbGeAlD
Sirolimus—FKBP1A—renal system—muscle cancer	0.00216	0.0216	CbGeAlD
Sirolimus—FKBP1A—cardiac atrium—muscle cancer	0.00193	0.0194	CbGeAlD
Sirolimus—MTOR—tendon—muscle cancer	0.00187	0.0188	CbGeAlD
Sirolimus—SLC47A1—renal system—muscle cancer	0.00185	0.0186	CbGeAlD
Sirolimus—SLCO1B1—renal system—muscle cancer	0.00183	0.0184	CbGeAlD
Sirolimus—MTOR—bone marrow—muscle cancer	0.00181	0.0182	CbGeAlD
Sirolimus—MTOR—vagina—muscle cancer	0.00174	0.0174	CbGeAlD
Sirolimus—FKBP1A—tendon—muscle cancer	0.00168	0.0169	CbGeAlD
Sirolimus—FKBP1A—bone marrow—muscle cancer	0.00163	0.0164	CbGeAlD
Sirolimus—MTOR—head—muscle cancer	0.0016	0.0161	CbGeAlD
Sirolimus—FKBP1A—vagina—muscle cancer	0.00156	0.0157	CbGeAlD
Sirolimus—MTOR—testis—muscle cancer	0.00155	0.0155	CbGeAlD
Sirolimus—SLC47A1—tendon—muscle cancer	0.00145	0.0145	CbGeAlD
Sirolimus—FKBP1A—head—muscle cancer	0.00144	0.0145	CbGeAlD
Sirolimus—FKBP1A—testis—muscle cancer	0.00139	0.014	CbGeAlD
Sirolimus—SLC47A1—vagina—muscle cancer	0.00134	0.0135	CbGeAlD
Sirolimus—SLC47A1—head—muscle cancer	0.00124	0.0124	CbGeAlD
Sirolimus—SLC47A1—testis—muscle cancer	0.0012	0.012	CbGeAlD
Sirolimus—CYP3A5—renal system—muscle cancer	0.000939	0.00942	CbGeAlD
Sirolimus—CYP3A4—renal system—muscle cancer	0.000705	0.00707	CbGeAlD
Sirolimus—CYP3A5—vagina—muscle cancer	0.00068	0.00682	CbGeAlD
Sirolimus—ABCB1—embryo—muscle cancer	0.000659	0.00661	CbGeAlD
Sirolimus—ABCB1—renal system—muscle cancer	0.000499	0.005	CbGeAlD
Sirolimus—ABCB1—bone marrow—muscle cancer	0.000377	0.00378	CbGeAlD
Sirolimus—ABCB1—vagina—muscle cancer	0.000361	0.00362	CbGeAlD
Sirolimus—ABCB1—head—muscle cancer	0.000334	0.00335	CbGeAlD
Sirolimus—ABCB1—testis—muscle cancer	0.000323	0.00323	CbGeAlD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.000318	0.00193	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000315	0.00191	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000312	0.00189	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—FOXO1—muscle cancer	0.00031	0.00188	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—KIT—muscle cancer	0.000304	0.00185	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—KIT—muscle cancer	0.000302	0.00184	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—KIT—muscle cancer	0.000301	0.00183	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—HMGA1—muscle cancer	0.000301	0.00183	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD34—muscle cancer	0.0003	0.00182	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—KIT—muscle cancer	0.0003	0.00182	CbGpPWpGaD
Sirolimus—Breast disorder—Methotrexate—muscle cancer	0.000299	0.00122	CcSEcCtD
Sirolimus—Leukopenia—Etoposide—muscle cancer	0.000298	0.00121	CcSEcCtD
Sirolimus—MTOR—Insulin Signaling—FOXO1—muscle cancer	0.000298	0.00181	CbGpPWpGaD
Sirolimus—Abdominal pain—Dactinomycin—muscle cancer	0.000297	0.00121	CcSEcCtD
Sirolimus—Body temperature increased—Dactinomycin—muscle cancer	0.000297	0.00121	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—MED12—muscle cancer	0.000296	0.0018	CbGpPWpGaD
Sirolimus—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000296	0.00121	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—FOXO1—muscle cancer	0.000296	0.0018	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000295	0.00179	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—FOXO1—muscle cancer	0.000295	0.00179	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000295	0.00179	CbGpPWpGaD
Sirolimus—Hypoglycaemia—Doxorubicin—muscle cancer	0.000294	0.0012	CcSEcCtD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000293	0.00178	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—FOXO1—muscle cancer	0.000293	0.00178	CbGpPWpGaD
Sirolimus—MTOR—LKB1 signaling events—TP53—muscle cancer	0.000293	0.00178	CbGpPWpGaD
Sirolimus—Loss of consciousness—Etoposide—muscle cancer	0.000292	0.00119	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—FOXO1—muscle cancer	0.000292	0.00177	CbGpPWpGaD
Sirolimus—Decreased appetite—Vincristine—muscle cancer	0.000291	0.00119	CcSEcCtD
Sirolimus—Cough—Etoposide—muscle cancer	0.00029	0.00118	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Vincristine—muscle cancer	0.000289	0.00118	CcSEcCtD
Sirolimus—Hyponatraemia—Doxorubicin—muscle cancer	0.000288	0.00117	CcSEcCtD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000288	0.00175	CbGpPWpGaD
Sirolimus—Hypertension—Etoposide—muscle cancer	0.000287	0.00117	CcSEcCtD
Sirolimus—Constipation—Vincristine—muscle cancer	0.000287	0.00117	CcSEcCtD
Sirolimus—Pain—Vincristine—muscle cancer	0.000287	0.00117	CcSEcCtD
Sirolimus—Osteoarthritis—Doxorubicin—muscle cancer	0.000287	0.00117	CcSEcCtD
Sirolimus—Asthma—Methotrexate—muscle cancer	0.000286	0.00117	CcSEcCtD
Sirolimus—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000286	0.00174	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIDINS220—muscle cancer	0.000286	0.00173	CbGpPWpGaD
Sirolimus—Chest pain—Etoposide—muscle cancer	0.000283	0.00116	CcSEcCtD
Sirolimus—Affect lability—Doxorubicin—muscle cancer	0.000282	0.00115	CcSEcCtD
Sirolimus—FGF2—Signaling by FGFR in disease—KIT—muscle cancer	0.000282	0.00171	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000282	0.00171	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—KIT—muscle cancer	0.000282	0.00171	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000281	0.00115	CcSEcCtD
Sirolimus—Pancreatitis—Methotrexate—muscle cancer	0.00028	0.00114	CcSEcCtD
Sirolimus—Discomfort—Etoposide—muscle cancer	0.00028	0.00114	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR—KIT—muscle cancer	0.000279	0.0017	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000279	0.00169	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000277	0.00168	CbGpPWpGaD
Sirolimus—Face oedema—Doxorubicin—muscle cancer	0.000277	0.00113	CcSEcCtD
Sirolimus—Hypersensitivity—Dactinomycin—muscle cancer	0.000276	0.00113	CcSEcCtD
Sirolimus—FGF2—Signaling by PDGF—KIT—muscle cancer	0.000276	0.00167	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000276	0.00167	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD34—muscle cancer	0.000275	0.00167	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—FOXO1—muscle cancer	0.000274	0.00167	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000274	0.00167	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000274	0.00167	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Vincristine—muscle cancer	0.000274	0.00112	CcSEcCtD
Sirolimus—Confusional state—Etoposide—muscle cancer	0.000274	0.00112	CcSEcCtD
Sirolimus—EIF4E—Gene Expression—MED12—muscle cancer	0.000273	0.00166	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—FOXO1—muscle cancer	0.000272	0.00165	CbGpPWpGaD
Sirolimus—Pancytopenia—Methotrexate—muscle cancer	0.000272	0.00111	CcSEcCtD
Sirolimus—Anaphylactic shock—Etoposide—muscle cancer	0.000272	0.00111	CcSEcCtD
Sirolimus—Mood swings—Doxorubicin—muscle cancer	0.000271	0.00111	CcSEcCtD
Sirolimus—Infection—Etoposide—muscle cancer	0.00027	0.0011	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00027	0.00164	CbGpPWpGaD
Sirolimus—Asthenia—Dactinomycin—muscle cancer	0.000269	0.0011	CcSEcCtD
Sirolimus—Blood creatinine increased—Doxorubicin—muscle cancer	0.000268	0.00109	CcSEcCtD
Sirolimus—MTOR—Signaling by PDGF—FOXO1—muscle cancer	0.000268	0.00163	CbGpPWpGaD
Sirolimus—Dysuria—Methotrexate—muscle cancer	0.000267	0.00109	CcSEcCtD
Sirolimus—Neutropenia—Methotrexate—muscle cancer	0.000267	0.00109	CcSEcCtD
Sirolimus—Dehydration—Doxorubicin—muscle cancer	0.000267	0.00109	CcSEcCtD
Sirolimus—FGF2—Signaling by SCF-KIT—MDM2—muscle cancer	0.000266	0.00162	CbGpPWpGaD
Sirolimus—Thrombocytopenia—Etoposide—muscle cancer	0.000266	0.00108	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000266	0.00108	CcSEcCtD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000266	0.00161	CbGpPWpGaD
Sirolimus—Tachycardia—Etoposide—muscle cancer	0.000265	0.00108	CcSEcCtD
Sirolimus—Body temperature increased—Vincristine—muscle cancer	0.000265	0.00108	CcSEcCtD
Sirolimus—Abdominal pain—Vincristine—muscle cancer	0.000265	0.00108	CcSEcCtD
Sirolimus—Liver function test abnormal—Doxorubicin—muscle cancer	0.000265	0.00108	CcSEcCtD
Sirolimus—MTOR—PI-3K cascade—MDM2—muscle cancer	0.000264	0.0016	CbGpPWpGaD
Sirolimus—Skin disorder—Etoposide—muscle cancer	0.000264	0.00108	CcSEcCtD
Sirolimus—Erectile dysfunction—Methotrexate—muscle cancer	0.000263	0.00107	CcSEcCtD
Sirolimus—Hyperhidrosis—Etoposide—muscle cancer	0.000263	0.00107	CcSEcCtD
Sirolimus—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000262	0.00107	CcSEcCtD
Sirolimus—Hypokalaemia—Doxorubicin—muscle cancer	0.000261	0.00106	CcSEcCtD
Sirolimus—FGF2—B Cell Activation—KIT—muscle cancer	0.000261	0.00158	CbGpPWpGaD
Sirolimus—Breast disorder—Doxorubicin—muscle cancer	0.000259	0.00106	CcSEcCtD
Sirolimus—Anorexia—Etoposide—muscle cancer	0.000259	0.00106	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000258	0.00105	CcSEcCtD
Sirolimus—MTOR—PI3K/AKT activation—MDM2—muscle cancer	0.000258	0.00157	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000258	0.00157	CbGpPWpGaD
Sirolimus—Diarrhoea—Dactinomycin—muscle cancer	0.000257	0.00105	CcSEcCtD
Sirolimus—Pneumonia—Methotrexate—muscle cancer	0.000257	0.00105	CcSEcCtD
Sirolimus—MTOR—GAB1 signalosome—MDM2—muscle cancer	0.000256	0.00155	CbGpPWpGaD
Sirolimus—Infestation—Methotrexate—muscle cancer	0.000255	0.00104	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—muscle cancer	0.000255	0.00104	CcSEcCtD
Sirolimus—FGF2—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000255	0.00155	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—FOXO1—muscle cancer	0.000254	0.00154	CbGpPWpGaD
Sirolimus—Hypotension—Etoposide—muscle cancer	0.000254	0.00103	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—muscle cancer	0.000254	0.00103	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—FOXO4—muscle cancer	0.000253	0.00154	CbGpPWpGaD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000253	0.00103	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—FOXO1—muscle cancer	0.000252	0.00153	CbGpPWpGaD
Sirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000252	0.00153	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KIT—muscle cancer	0.000251	0.00152	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—MDM2—muscle cancer	0.000251	0.00152	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.00025	0.00152	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.00025	0.00152	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.00025	0.00151	CbGpPWpGaD
Sirolimus—Abdominal distension—Doxorubicin—muscle cancer	0.000249	0.00102	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—muscle cancer	0.000249	0.00101	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—muscle cancer	0.000248	0.00101	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—muscle cancer	0.000248	0.00101	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—muscle cancer	0.000248	0.00101	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—muscle cancer	0.000248	0.00101	CcSEcCtD
Sirolimus—Hypersensitivity—Vincristine—muscle cancer	0.000247	0.00101	CcSEcCtD
Sirolimus—EIF4E—Metabolism of proteins—IGF2—muscle cancer	0.000245	0.00149	CbGpPWpGaD
Sirolimus—Sweating—Methotrexate—muscle cancer	0.000245	0.000997	CcSEcCtD
Sirolimus—MTOR—ErbB Signaling Pathway—TP53—muscle cancer	0.000244	0.00148	CbGpPWpGaD
Sirolimus—Paraesthesia—Etoposide—muscle cancer	0.000244	0.000994	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—muscle cancer	0.000243	0.000992	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000243	0.00148	CbGpPWpGaD
Sirolimus—Pancreatitis—Doxorubicin—muscle cancer	0.000243	0.00099	CcSEcCtD
Sirolimus—Dyspnoea—Etoposide—muscle cancer	0.000242	0.000987	CcSEcCtD
Sirolimus—Somnolence—Etoposide—muscle cancer	0.000241	0.000984	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—muscle cancer	0.000241	0.000983	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—muscle cancer	0.000241	0.000981	CcSEcCtD
Sirolimus—Asthenia—Vincristine—muscle cancer	0.000241	0.000981	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.00024	0.00146	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—MDM2—muscle cancer	0.000239	0.00145	CbGpPWpGaD
Sirolimus—Vomiting—Dactinomycin—muscle cancer	0.000239	0.000973	CcSEcCtD
Sirolimus—FGF2—Signaling by FGFR—MDM2—muscle cancer	0.000238	0.00145	CbGpPWpGaD
Sirolimus—Bronchitis—Doxorubicin—muscle cancer	0.000238	0.000971	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB2—MDM2—muscle cancer	0.000237	0.00144	CbGpPWpGaD
Sirolimus—Rash—Dactinomycin—muscle cancer	0.000237	0.000965	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB4—KIT—muscle cancer	0.000236	0.00143	CbGpPWpGaD
Sirolimus—Decreased appetite—Etoposide—muscle cancer	0.000236	0.000963	CcSEcCtD
Sirolimus—FGF2—DAP12 signaling—MDM2—muscle cancer	0.000236	0.00143	CbGpPWpGaD
Sirolimus—Pancytopenia—Doxorubicin—muscle cancer	0.000235	0.000959	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Etoposide—muscle cancer	0.000234	0.000956	CcSEcCtD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000232	0.00141	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TP53—muscle cancer	0.000232	0.00141	CbGpPWpGaD
Sirolimus—Pain—Etoposide—muscle cancer	0.000232	0.000947	CcSEcCtD
Sirolimus—Constipation—Etoposide—muscle cancer	0.000232	0.000947	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—muscle cancer	0.000232	0.000944	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—muscle cancer	0.000232	0.000944	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00023	0.000939	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—muscle cancer	0.00023	0.000938	CcSEcCtD
Sirolimus—Diarrhoea—Vincristine—muscle cancer	0.000229	0.000935	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—muscle cancer	0.000229	0.000934	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—muscle cancer	0.000229	0.000933	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—muscle cancer	0.000227	0.000927	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—muscle cancer	0.000226	0.000922	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—KIT—muscle cancer	0.000226	0.00137	CbGpPWpGaD
Sirolimus—Weight increased—Doxorubicin—muscle cancer	0.000225	0.000919	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR—KIT—muscle cancer	0.000224	0.00136	CbGpPWpGaD
Sirolimus—Urethral disorder—Methotrexate—muscle cancer	0.000224	0.000915	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—muscle cancer	0.000224	0.000914	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—muscle cancer	0.000224	0.000912	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—muscle cancer	0.000223	0.000911	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB2—KIT—muscle cancer	0.000223	0.00136	CbGpPWpGaD
Sirolimus—Nausea—Dactinomycin—muscle cancer	0.000223	0.000909	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—KIT—muscle cancer	0.000222	0.00135	CbGpPWpGaD
Sirolimus—Pneumonia—Doxorubicin—muscle cancer	0.000222	0.000906	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—muscle cancer	0.000222	0.000905	CcSEcCtD
Sirolimus—FGF2—Signaling by FGFR in disease—MDM2—muscle cancer	0.000222	0.00135	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000222	0.00135	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—MDM2—muscle cancer	0.000222	0.00135	CbGpPWpGaD
Sirolimus—Dizziness—Vincristine—muscle cancer	0.000222	0.000904	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—muscle cancer	0.000221	0.0009	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—muscle cancer	0.000221	0.0009	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—muscle cancer	0.000221	0.0009	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR—MDM2—muscle cancer	0.00022	0.00133	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000219	0.00133	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000218	0.00132	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—MDM2—muscle cancer	0.000217	0.00132	CbGpPWpGaD
Sirolimus—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000216	0.000883	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—KIDINS220—muscle cancer	0.000216	0.00131	CbGpPWpGaD
Sirolimus—Stomatitis—Doxorubicin—muscle cancer	0.000215	0.000878	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—muscle cancer	0.000215	0.000875	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—muscle cancer	0.000215	0.000875	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—muscle cancer	0.000215	0.000875	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—muscle cancer	0.000215	0.000875	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—muscle cancer	0.000213	0.00087	CcSEcCtD
Sirolimus—Vomiting—Vincristine—muscle cancer	0.000213	0.000869	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—muscle cancer	0.000212	0.000866	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—muscle cancer	0.000212	0.000863	CcSEcCtD
Sirolimus—Rash—Vincristine—muscle cancer	0.000211	0.000862	CcSEcCtD
Sirolimus—Dermatitis—Vincristine—muscle cancer	0.000211	0.000861	CcSEcCtD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000211	0.00128	CbGpPWpGaD
Sirolimus—Haematuria—Doxorubicin—muscle cancer	0.000211	0.000859	CcSEcCtD
Sirolimus—Headache—Vincristine—muscle cancer	0.00021	0.000856	CcSEcCtD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000209	0.00127	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000209	0.00127	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KIT—muscle cancer	0.000209	0.00127	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KIT—muscle cancer	0.000209	0.00127	CbGpPWpGaD
Sirolimus—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000209	0.000852	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000209	0.00127	CbGpPWpGaD
Sirolimus—Epistaxis—Doxorubicin—muscle cancer	0.000208	0.000849	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—muscle cancer	0.000208	0.000847	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—KIT—muscle cancer	0.000207	0.00126	CbGpPWpGaD
Sirolimus—Sinusitis—Doxorubicin—muscle cancer	0.000207	0.000845	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—muscle cancer	0.000207	0.000843	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—muscle cancer	0.000206	0.000841	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000206	0.00125	CbGpPWpGaD
Sirolimus—Chills—Methotrexate—muscle cancer	0.000205	0.000838	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000205	0.00125	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—MDM2—muscle cancer	0.000205	0.00125	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KIT—muscle cancer	0.000205	0.00124	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD34—muscle cancer	0.000204	0.00124	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—FOXO4—muscle cancer	0.000204	0.00124	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000201	0.00122	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—muscle cancer	0.000201	0.00122	CbGpPWpGaD
Sirolimus—Hypersensitivity—Etoposide—muscle cancer	0.0002	0.000816	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—muscle cancer	0.000199	0.000813	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—muscle cancer	0.000199	0.000812	CcSEcCtD
Sirolimus—Nausea—Vincristine—muscle cancer	0.000199	0.000812	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—muscle cancer	0.000199	0.00081	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—muscle cancer	0.000198	0.000808	CcSEcCtD
Sirolimus—MTOR—Signaling by SCF-KIT—MDM2—muscle cancer	0.000198	0.0012	CbGpPWpGaD
Sirolimus—Hypoaesthesia—Doxorubicin—muscle cancer	0.000197	0.000804	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—muscle cancer	0.000197	0.000802	CcSEcCtD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000197	0.00119	CbGpPWpGaD
Sirolimus—Urinary tract disorder—Doxorubicin—muscle cancer	0.000196	0.000798	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—muscle cancer	0.000195	0.000796	CcSEcCtD
Sirolimus—Asthenia—Etoposide—muscle cancer	0.000195	0.000794	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—muscle cancer	0.000195	0.000794	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—FOXO4—muscle cancer	0.000195	0.00118	CbGpPWpGaD
Sirolimus—Urethral disorder—Doxorubicin—muscle cancer	0.000194	0.000792	CcSEcCtD
Sirolimus—MTOR—B Cell Activation—KIT—muscle cancer	0.000194	0.00117	CbGpPWpGaD
Sirolimus—Back pain—Methotrexate—muscle cancer	0.000193	0.000786	CcSEcCtD
Sirolimus—Pruritus—Etoposide—muscle cancer	0.000192	0.000783	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—KIT—muscle cancer	0.000192	0.00117	CbGpPWpGaD
Sirolimus—Visual impairment—Doxorubicin—muscle cancer	0.000191	0.000779	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000189	0.00115	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000187	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000187	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—FOXO1—muscle cancer	0.000187	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—FOXO4—muscle cancer	0.000187	0.00113	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—MDM2—muscle cancer	0.000186	0.00113	CbGpPWpGaD
Sirolimus—Diarrhoea—Etoposide—muscle cancer	0.000186	0.000758	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000185	0.00112	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Methotrexate—muscle cancer	0.000185	0.000754	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—muscle cancer	0.000185	0.000754	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—muscle cancer	0.000184	0.000751	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—muscle cancer	0.000184	0.00075	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—muscle cancer	0.00018	0.000733	CcSEcCtD
Sirolimus—Malaise—Methotrexate—muscle cancer	0.00018	0.000733	CcSEcCtD
Sirolimus—Dizziness—Etoposide—muscle cancer	0.00018	0.000732	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—muscle cancer	0.000179	0.00073	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—muscle cancer	0.000179	0.000729	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—muscle cancer	0.000178	0.000727	CcSEcCtD
Sirolimus—Chills—Doxorubicin—muscle cancer	0.000178	0.000725	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—MDM2—muscle cancer	0.000178	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—MDM2—muscle cancer	0.000177	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—VEGFA—muscle cancer	0.000177	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—MDM2—muscle cancer	0.000176	0.00107	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—MDM2—muscle cancer	0.000175	0.00106	CbGpPWpGaD
Sirolimus—Cough—Methotrexate—muscle cancer	0.000174	0.000709	CcSEcCtD
Sirolimus—Vomiting—Etoposide—muscle cancer	0.000173	0.000704	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—muscle cancer	0.000173	0.000704	CcSEcCtD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000173	0.00105	CbGpPWpGaD
Sirolimus—Rash—Etoposide—muscle cancer	0.000171	0.000698	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—muscle cancer	0.000171	0.000697	CcSEcCtD
Sirolimus—Headache—Etoposide—muscle cancer	0.00017	0.000694	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—muscle cancer	0.00017	0.000693	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—muscle cancer	0.00017	0.000692	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—muscle cancer	0.00017	0.000692	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—muscle cancer	0.00017	0.000692	CcSEcCtD
Sirolimus—Tension—Doxorubicin—muscle cancer	0.000169	0.000691	CcSEcCtD
Sirolimus—FKBP1A—Disease—ENO2—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000169	0.00103	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000169	0.000687	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—muscle cancer	0.000168	0.000684	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—muscle cancer	0.000168	0.000683	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—muscle cancer	0.000167	0.000681	CcSEcCtD
Sirolimus—FGF2—Immune System—CD34—muscle cancer	0.000167	0.00101	CbGpPWpGaD
Sirolimus—Muscle spasms—Doxorubicin—muscle cancer	0.000166	0.000677	CcSEcCtD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000165	0.001	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—MDM2—muscle cancer	0.000165	0.001	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—MDM2—muscle cancer	0.000165	0.001	CbGpPWpGaD
Sirolimus—Confusional state—Methotrexate—muscle cancer	0.000164	0.000669	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—MDM2—muscle cancer	0.000163	0.000991	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—FOXO1—muscle cancer	0.000163	0.000988	CbGpPWpGaD
Sirolimus—Anaphylactic shock—Methotrexate—muscle cancer	0.000163	0.000663	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000162	0.000982	CbGpPWpGaD
Sirolimus—Infection—Methotrexate—muscle cancer	0.000162	0.000659	CcSEcCtD
Sirolimus—Nausea—Etoposide—muscle cancer	0.000161	0.000658	CcSEcCtD
Sirolimus—MTOR—Signaling by PDGF—MDM2—muscle cancer	0.000161	0.000978	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIDINS220—muscle cancer	0.000161	0.000975	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Doxorubicin—muscle cancer	0.00016	0.000653	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—muscle cancer	0.00016	0.00065	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—muscle cancer	0.00016	0.00065	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—muscle cancer	0.000159	0.000649	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—muscle cancer	0.000159	0.000647	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000159	0.000962	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000158	0.00096	CbGpPWpGaD
Sirolimus—Skin disorder—Methotrexate—muscle cancer	0.000158	0.000644	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—muscle cancer	0.000157	0.000641	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—muscle cancer	0.000156	0.000635	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—muscle cancer	0.000155	0.000632	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—muscle cancer	0.000155	0.000631	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—muscle cancer	0.000154	0.00063	CcSEcCtD
Sirolimus—FKBP1A—Disease—HMGA1—muscle cancer	0.000154	0.000934	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTCH1—muscle cancer	0.000153	0.00093	CbGpPWpGaD
Sirolimus—Palpitations—Doxorubicin—muscle cancer	0.000153	0.000622	CcSEcCtD
Sirolimus—MTOR—B Cell Activation—MDM2—muscle cancer	0.000152	0.000925	CbGpPWpGaD
Sirolimus—Hypotension—Methotrexate—muscle cancer	0.000152	0.00062	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—muscle cancer	0.000152	0.000618	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—MDM2—muscle cancer	0.000151	0.000918	CbGpPWpGaD
Sirolimus—Cough—Doxorubicin—muscle cancer	0.000151	0.000614	CcSEcCtD
Sirolimus—EIF4E—Immune System—FOXO1—muscle cancer	0.000151	0.000914	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000151	0.000914	CbGpPWpGaD
Sirolimus—Hypertension—Doxorubicin—muscle cancer	0.000149	0.000608	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000148	0.000604	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—muscle cancer	0.000147	0.0006	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—muscle cancer	0.000147	0.000599	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—muscle cancer	0.000147	0.000599	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—muscle cancer	0.000147	0.000599	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—muscle cancer	0.000146	0.000597	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—muscle cancer	0.000146	0.000596	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000146	0.000595	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000146	0.000885	CbGpPWpGaD
Sirolimus—Discomfort—Doxorubicin—muscle cancer	0.000145	0.000592	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—muscle cancer	0.000145	0.000591	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—muscle cancer	0.000145	0.00059	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—FOXO4—muscle cancer	0.000144	0.000876	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—FOXO1—muscle cancer	0.000144	0.000872	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000143	0.000871	CbGpPWpGaD
Sirolimus—Dyspepsia—Methotrexate—muscle cancer	0.000143	0.000584	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—KIT—muscle cancer	0.000142	0.000865	CbGpPWpGaD
Sirolimus—Confusional state—Doxorubicin—muscle cancer	0.000142	0.000579	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000142	0.000862	CbGpPWpGaD
Sirolimus—Decreased appetite—Methotrexate—muscle cancer	0.000141	0.000577	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—muscle cancer	0.000141	0.000574	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—muscle cancer	0.000141	0.000574	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00014	0.000573	CcSEcCtD
Sirolimus—Infection—Doxorubicin—muscle cancer	0.00014	0.000571	CcSEcCtD
Sirolimus—Pain—Methotrexate—muscle cancer	0.000139	0.000567	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—FOXO4—muscle cancer	0.000139	0.000842	CbGpPWpGaD
Sirolimus—Shock—Doxorubicin—muscle cancer	0.000139	0.000565	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—muscle cancer	0.000138	0.000563	CcSEcCtD
Sirolimus—FKBP1A—Disease—FOXO4—muscle cancer	0.000138	0.000838	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—FOXO1—muscle cancer	0.000138	0.000838	CbGpPWpGaD
Sirolimus—Thrombocytopenia—Doxorubicin—muscle cancer	0.000138	0.000562	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—muscle cancer	0.000137	0.00056	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—muscle cancer	0.000137	0.000558	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—muscle cancer	0.000136	0.000555	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—muscle cancer	0.000134	0.000547	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—muscle cancer	0.000134	0.000547	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—FH—muscle cancer	0.000133	0.000808	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Methotrexate—muscle cancer	0.000133	0.000542	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—FOXO4—muscle cancer	0.000132	0.0008	CbGpPWpGaD
Sirolimus—Hypotension—Doxorubicin—muscle cancer	0.000132	0.000537	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CNR1—muscle cancer	0.000129	0.000785	CbGpPWpGaD
Sirolimus—Body temperature increased—Methotrexate—muscle cancer	0.000129	0.000524	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—muscle cancer	0.000129	0.000524	CcSEcCtD
Sirolimus—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000128	0.000779	CbGpPWpGaD
Sirolimus—FGF2—Disease—ENO2—muscle cancer	0.000128	0.000779	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000128	0.000523	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—muscle cancer	0.000127	0.000519	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—muscle cancer	0.000126	0.000516	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—muscle cancer	0.000126	0.000512	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—muscle cancer	0.000125	0.000511	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—muscle cancer	0.000124	0.000506	CcSEcCtD
Sirolimus—MTOR—Immune System—CD34—muscle cancer	0.000124	0.000751	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDKN2A—muscle cancer	0.000123	0.000749	CbGpPWpGaD
Sirolimus—Decreased appetite—Doxorubicin—muscle cancer	0.000122	0.000499	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—FH—muscle cancer	0.000122	0.000742	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000122	0.000496	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—muscle cancer	0.00012	0.000491	CcSEcCtD
Sirolimus—Pain—Doxorubicin—muscle cancer	0.00012	0.000491	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—muscle cancer	0.00012	0.000489	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.00012	0.000727	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—MDM2—muscle cancer	0.00012	0.000726	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000119	0.000719	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—muscle cancer	0.000117	0.000476	CcSEcCtD
Sirolimus—FGF2—Disease—HMGA1—muscle cancer	0.000117	0.000708	CbGpPWpGaD
Sirolimus—Feeling abnormal—Doxorubicin—muscle cancer	0.000116	0.000473	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000115	0.00047	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—muscle cancer	0.000115	0.000469	CcSEcCtD
Sirolimus—EIF4E—Immune System—KIT—muscle cancer	0.000115	0.000696	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FOXO4—muscle cancer	0.000113	0.000688	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTCH1—muscle cancer	0.000112	0.000682	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MDM2—muscle cancer	0.000112	0.000681	CbGpPWpGaD
Sirolimus—Body temperature increased—Doxorubicin—muscle cancer	0.000111	0.000454	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—muscle cancer	0.000111	0.000454	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—muscle cancer	0.000111	0.000454	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—KIT—muscle cancer	0.000109	0.000665	CbGpPWpGaD
Sirolimus—Dizziness—Methotrexate—muscle cancer	0.000108	0.000439	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000107	0.000651	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—FOXO1—muscle cancer	0.000107	0.000647	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF2—muscle cancer	0.000106	0.000642	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KIT—muscle cancer	0.000105	0.000638	CbGpPWpGaD
Sirolimus—FGF2—Disease—FOXO4—muscle cancer	0.000105	0.000635	CbGpPWpGaD
Sirolimus—Hypersensitivity—Doxorubicin—muscle cancer	0.000104	0.000423	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—muscle cancer	0.000103	0.000422	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000103	0.000623	CbGpPWpGaD
Sirolimus—Rash—Methotrexate—muscle cancer	0.000103	0.000418	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—muscle cancer	0.000102	0.000418	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—FOXO1—muscle cancer	0.000102	0.000622	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—FOXO1—muscle cancer	0.000102	0.000619	CbGpPWpGaD
Sirolimus—Headache—Methotrexate—muscle cancer	0.000102	0.000415	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—muscle cancer	0.000101	0.000412	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—muscle cancer	9.97e-05	0.000406	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—FOXO1—muscle cancer	9.73e-05	0.000591	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FOXO4—muscle cancer	9.67e-05	0.000587	CbGpPWpGaD
Sirolimus—Nausea—Methotrexate—muscle cancer	9.66e-05	0.000394	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—muscle cancer	9.64e-05	0.000393	CcSEcCtD
Sirolimus—MTOR—Disease—ENO2—muscle cancer	9.52e-05	0.000578	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CNR1—muscle cancer	9.49e-05	0.000576	CbGpPWpGaD
Sirolimus—Dizziness—Doxorubicin—muscle cancer	9.31e-05	0.00038	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—muscle cancer	9.08e-05	0.000551	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MDM2—muscle cancer	9.03e-05	0.000548	CbGpPWpGaD
Sirolimus—Vomiting—Doxorubicin—muscle cancer	8.96e-05	0.000365	CcSEcCtD
Sirolimus—Rash—Doxorubicin—muscle cancer	8.88e-05	0.000362	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—muscle cancer	8.87e-05	0.000362	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—FH—muscle cancer	8.83e-05	0.000536	CbGpPWpGaD
Sirolimus—Headache—Doxorubicin—muscle cancer	8.82e-05	0.00036	CcSEcCtD
Sirolimus—MTOR—Disease—HMGA1—muscle cancer	8.66e-05	0.000525	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MDM2—muscle cancer	8.62e-05	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTCH1—muscle cancer	8.52e-05	0.000517	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FOXO4—muscle cancer	8.41e-05	0.00051	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FOXO1—muscle cancer	8.37e-05	0.000508	CbGpPWpGaD
Sirolimus—Nausea—Doxorubicin—muscle cancer	8.37e-05	0.000341	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—MDM2—muscle cancer	8.28e-05	0.000503	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KIT—muscle cancer	8.12e-05	0.000493	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KIT—muscle cancer	7.8e-05	0.000474	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KIT—muscle cancer	7.77e-05	0.000472	CbGpPWpGaD
Sirolimus—MTOR—Disease—FOXO4—muscle cancer	7.76e-05	0.000471	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF2—muscle cancer	7.76e-05	0.000471	CbGpPWpGaD
Sirolimus—FGF2—Disease—FOXO1—muscle cancer	7.73e-05	0.000469	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MED12—muscle cancer	7.52e-05	0.000457	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KIT—muscle cancer	7.42e-05	0.00045	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—muscle cancer	7.41e-05	0.00045	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FOXO4—muscle cancer	7.33e-05	0.000445	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CNR1—muscle cancer	7.19e-05	0.000437	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FOXO1—muscle cancer	7.14e-05	0.000433	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MED12—muscle cancer	6.91e-05	0.000419	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—muscle cancer	6.86e-05	0.000417	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—muscle cancer	6.86e-05	0.000416	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.67e-05	0.000405	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FH—muscle cancer	6.67e-05	0.000405	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.43e-05	0.00039	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MDM2—muscle cancer	6.4e-05	0.000388	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIT—muscle cancer	6.38e-05	0.000387	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTCH1—muscle cancer	6.32e-05	0.000384	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—muscle cancer	6.3e-05	0.000382	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FOXO1—muscle cancer	6.21e-05	0.000377	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—MDM2—muscle cancer	6.14e-05	0.000373	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MDM2—muscle cancer	6.12e-05	0.000371	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—muscle cancer	5.9e-05	0.000358	CbGpPWpGaD
Sirolimus—FGF2—Disease—KIT—muscle cancer	5.89e-05	0.000357	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF2—muscle cancer	5.88e-05	0.000357	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MDM2—muscle cancer	5.84e-05	0.000355	CbGpPWpGaD
Sirolimus—MTOR—Disease—FOXO1—muscle cancer	5.73e-05	0.000348	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIT—muscle cancer	5.44e-05	0.00033	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FOXO4—muscle cancer	5.44e-05	0.00033	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FOXO1—muscle cancer	5.41e-05	0.000328	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.36e-05	0.000326	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CNR1—muscle cancer	5.34e-05	0.000324	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.07e-05	0.000307	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MDM2—muscle cancer	5.02e-05	0.000305	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MED12—muscle cancer	4.99e-05	0.000303	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—muscle cancer	4.73e-05	0.000287	CbGpPWpGaD
Sirolimus—FGF2—Disease—MDM2—muscle cancer	4.64e-05	0.000281	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—muscle cancer	4.55e-05	0.000276	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—muscle cancer	4.47e-05	0.000271	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—muscle cancer	4.44e-05	0.000269	CbGpPWpGaD
Sirolimus—MTOR—Disease—KIT—muscle cancer	4.37e-05	0.000265	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF2—muscle cancer	4.36e-05	0.000265	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MDM2—muscle cancer	4.28e-05	0.00026	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—muscle cancer	4.12e-05	0.00025	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FH—muscle cancer	4.11e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FOXO1—muscle cancer	4.02e-05	0.000244	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.83e-05	0.000232	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MED12—muscle cancer	3.77e-05	0.000229	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MDM2—muscle cancer	3.73e-05	0.000226	CbGpPWpGaD
Sirolimus—MTOR—Disease—MDM2—muscle cancer	3.44e-05	0.000209	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—muscle cancer	3.43e-05	0.000208	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—muscle cancer	3.35e-05	0.000203	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—muscle cancer	3.32e-05	0.000201	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—muscle cancer	3.25e-05	0.000197	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—muscle cancer	3.25e-05	0.000197	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—muscle cancer	3.06e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—muscle cancer	2.47e-05	0.00015	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—muscle cancer	2.46e-05	0.000149	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—muscle cancer	2.41e-05	0.000146	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—muscle cancer	2.39e-05	0.000145	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MED12—muscle cancer	2.32e-05	0.000141	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—muscle cancer	2.19e-05	0.000133	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—muscle cancer	2.12e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—muscle cancer	1.86e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—muscle cancer	1.83e-05	0.000111	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—muscle cancer	1.58e-05	9.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—muscle cancer	1.38e-05	8.39e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—muscle cancer	1.2e-05	7.26e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—muscle cancer	7.37e-06	4.47e-05	CbGpPWpGaD
